ARDX Earnings Date: Nov 3, 2026 (Estimated) — Ardelyx, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARDX's next earnings date?
Ardelyx, Inc. (ARDX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.01 on revenue of $128.7M.
How did ARDX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Ardelyx, Inc. posted EPS of -$0.07 versus the -$0.07 estimate, a miss of 75.0%. Revenue was $118.1M against a $121.0M estimate. The stock's 1-day post-earnings move was -17.9%.
How much does ARDX stock move after earnings?
ARDX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.9% (up or down) in the day after earnings.
About Ardelyx, Inc.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.07 | -0.07 | -75.00% | $118.1M | ❌ Miss | -17.86% | -19.71% | -22.38% |
| 2026-04-30 | Q1 2026 | -0.14 | -0.15 | -7.14% | $94.5M | ❌ Miss | +8.69% | +10.27% | -9.48% |
| 2026-02-19 | Q4 2025 | 0.01 | 0.00 | -100.00% | $125.2M | ❌ Miss | -14.99% | -1.63% | -21.22% |
| 2025-10-30 | Q3 2025 | -0.06 | 0.00 | +100.00% | $110.3M | ✅ Beat | +20.96% | +12.77% | +11.58% |
| 2025-08-04 | Q2 2025 | -0.13 | -0.08 | +38.46% | $97.7M | ✅ Beat | +16.86% | +23.01% | +48.29% |
| 2025-02-20 | Q4 2024 | 0.00 | 0.02 | +100.00% | $116.1M | ✅ Beat | -10.06% | -19.81% | -13.68% |
| 2024-10-31 | Q3 2024 | -0.05 | 0.00 | +100.00% | $98.2M | ✅ Beat | +3.75% | +8.69% | -5.62% |
| 2024-08-01 | Q2 2024 | -0.11 | -0.07 | +36.36% | $73.2M | ✅ Beat | +10.00% | +6.73% | +12.36% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $204.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 57.8% | $118.1M | +31.1% | $111.0M | $67.8M | $90.1M | $105.5M |
| Product, IBSRELA | 42.2% | $86.2M | +32.6% | $53.8M | — | $65.0M | $78.2M |
| License | 0.0% | $96K | +380.0% | $22K | $5.0M | $20K | $25K |
By region
FY2025 · $407.3M total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 92.8% | $377.8M | +18.4% | — | — | — | $15.6M |
| Asia Pacific | 7.2% | $29.2M | +37297.4% | $5.3M | $6.8M | $10.1M | $36.5M |
| North America | 0.1% | $342K | -97.6% | — | $806K | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.